Clinical Response to Infliximab after Secondary Failure with Adalimumab or Certolizumab Pegol in Crohn's Disease

被引：0
|
作者：
Trivella, Juan [1 ]
Yarur, Andres [1 ]
Moroney, James [1 ]
Deshpande, Amar [1 ]
Abreu, Maria [1 ]
Sussman, Daniel [1 ]
机构：
[1] Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2013年 / 108卷
关键词：
D O I：
10.14309/00000434-201310001-01855
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1855
引用
收藏
页码：S560 / S561
页数：2
相关论文
共 50 条
  • [41] Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series
    Cordero Ruiz, Patricia
    Castro Marquez, Cristina
    Mendez Rufian, Vanesa
    Castro Laria, Luisa
    Caunedo Alvarez, Angel
    Romero Vazquez, Javier
    Herrerias Gutierrez, Juan Manuel
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2011, 103 (06) : 294 - 298
  • [42] Certolizumab Pegol for the Management of Crohn's Disease in Adults
    Rivkin, Anastasia
    CLINICAL THERAPEUTICS, 2009, 31 (06) : 1158 - 1176
  • [43] Pharmakokinetics of Certolizumab Pegol Induction in Crohn's Disease
    Wolf, Douglas C.
    Wolf, Christine
    GASTROENTEROLOGY, 2015, 148 (04) : S867 - S868
  • [44] Maintenance therapy with certolizumab pegol for Crohn's disease
    Schreiber, Stefan
    Khaliq-Kareemi, Mani
    Lawrance, Ian C.
    Thomsen, Ole Ostergaard
    Hanauer, Stephen B.
    McColm, Juliet
    Bloomfield, Ralph
    Sandborn, William J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03): : 239 - 250
  • [45] Assessment of the Efficacy of Certolizumab Pegol in the Maintenance of Response for the Treatment of Crohn's Disease
    Lee, Scott D.
    Ko, Cynthia W.
    Wahbeh, Ghassan
    Cullinan, Cory
    Etter, Scott
    Sinanan, Mika N.
    Wheat, Chelle
    GASTROENTEROLOGY, 2011, 140 (05) : S282 - S282
  • [46] Certolizumab pegol for induction of remission in Crohn's disease
    Yamazaki, Hajime
    So, Ryuhei
    Matsuoka, Katsuyoshi
    Kobayashi, Taku
    Shinzaki, Shinichiro
    Matsuura, Minoru
    Okabayashi, Shinji
    Kataoka, Yuki
    Tsujimoto, Yasushi
    Furukawa, Toshi A.
    Watanabe, Norio
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (08):
  • [47] Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease
    Tun, Gloria S. Z.
    Lobo, Alan J.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (02) : 317 - 327
  • [48] Certolizumab pegol is efficacious in Crohn's disease patients who have failed infliximab regardless of concomitant therapy or reason for failure
    Abreu, Maria
    Sandborn, William
    D'Haens, Geert
    Colombed, Jean-Frederic
    Mitchev, Krassimir
    Raedler, Andreas
    Lee, Scott
    Fedorak, Richard
    Vermeire, Severine
    Rutgeerts, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S430 - S431
  • [49] Randomized Clinical Trial for Clinical Response Evaluation in Crohn's Disease: Infliximab Versus Adalimumab
    Baima, Julio
    Lima, Talles
    Moreira, Alecssandro
    de Barros, Jaqueline
    Dorna, Mariana
    da Silva, Rosemary
    Sibia, Carina
    Renosto, Fernanda
    Farinelli, Elen
    Saad-Hossne, Rogerio
    Sassaki, Ligia
    INFLAMMATORY BOWEL DISEASES, 2016, 22 : S30 - S30
  • [50] HEALTHCARE SERVICE UTILIZATION AND COSTS OF CERTOLIZUMAB PEGOL VERSUS INFLIXIMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE
    Tkacz, Joseph
    Lee, Edward
    Low, Robert
    Stark, Jeffrey
    Yassine, Mohamed
    Brady, Brenna L.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S15 - S15
12345